Afabicin diolamine

The rapid growth of antimicrobial resistance (AMR) is staggering, particularly when considering the slow rate at which new antibiotics are being developed and made available to patients1 International health authorities, including the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC), continue to sound the alarm to promote increased preparedness, save human lives and avoid a heavy financial burden on healthcare systems2,3 Debiopharm is one of the main sponsors and panel participants of the 2023 World Antimicrobial Resistance (World AMR) Congress in Philadelphia, Pennsylvania — a conference gathering key AMR stakeholders including international government agencies, policy associations, and healthcare industry professionals LAUSANNE, Switzerland--(BUSINESS WIRE)-- Debiopharm ( ), a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced their participation in the keynote panel and antibiotic development track sessions at the 2023 World AMR conference from September 7th – 8th, 2023. Debiopharm’s panelist Morgane Vanbiervliet, Market Intelligence & Business Development Manager, Infectious Diseases, is part of the AMR preparedness keynote panel to be moderated by Bruce Y. Lee from Forbes and involving representatives from the CDC, Menarini Group, IFPMA and the AMR Action Fund. A further Debiopharm-sponsored breakout session, moderated by Dr. Ricardo Chaves, Executive Medical Director, will feature Dr. L. Clifford McDonald, Associate Director for Science in the Division of Healthcare Quality Promotion at the CDC, explaining the relevance of novel microbiome-sparing antibiotics in combating AMR, and the potential need for new regulatory approval and reimbursement pathways.* “It’s important to harness these open dialogues between public organizations and the infectious disease industry experts at World AMR to produce action that can prepare us to face the emerging wave of resistant infections,” explained Morgane Vanbiervliet, Market Intelligence & Business Development Manager, Infectious Diseases, Debiopharm. “We know that uncontrollable infectious diseases are everybody’s business, and that our preparation efforts must involve the reinforcement of prevention measures, better stewardship education, and sustainable market pathways for new effective treatments.” “The CDC recognizes the importance of the human microbiome as it provides key resistance to human colonization with multidrug-resistant pathogens. Along with products that will reduce the degree of colonization (i.e. pathogen reduction), or drugs that will restore the microbiome, we need therapeutic antibiotics that spare the microbiome, by being highly-selective for only specific pathogens.” expressed Dr. L. Clifford McDonald, Associate Director for Science in the Division of Healthcare Quality Promotion, CDC. Last year’s special report from the CDC on the impact of COVID-19 on antimicrobial resistance revealed that 6 of the 18 most alarming bacterial menaces cost the US more that $4.6 billion each year and thousands of human lives.4 The agency’s 18 bacterial and fungal threats include 2 pathogens for which Debiopharm is currently developing new antibiotics: Neisseria gonorrhoeae and methicillin-resistant Staphylococcus aureus. Debiopharm’s FabI inhibitor therapies are part of a new pathogen-specific antibiotic class that is being researched for its capacity to effectively treat a single type of bacteria and thereby preserve the microbiome and avoid subsequent spread of AMR. World AMR 2023 Session details Congress agenda Speakers Keynote panel Sept. 7th 08:35 EST How can we push AMR to the forefront of preparedness? Morgane Vanbiervliet, Market Intelligence & Business Development Manager, Infectious Diseases, Debiopharm + other invited speakers Panel discussion Sept. 7th 11:00–11:30 EST Antibiotic Development stream The public health case for microbiome-sparing antibiotics: Potential need for new pathways in regulatory approval and reimbursement Moderator: Dr. Ricardo Chaves Executive Medical Director Debiopharm Speaker: Dr.L. Clifford McDonald, Associate Director for Science in the Division of Healthcare Quality Promotion, CDC About afabicin Afabicin (Debio 1450) is Debiopharm’s first-in-class FabI inhibitor against Staphylococcus spp., whose methicillin-resistant Staphylococcus aureus (MRSA) strains are high on the WHO global priority pathogen list and deemed a “serious threat” by the CDC. Afabicin can be administered orally or IV and selectively targets Staphylococcus’ essential bacterial fatty acid biosynthesis. Promising results have been obtained in a comparative double-blind Phase 2 trial with afabicin in acute bacterial skin and skin structure infections. Currently, a Phase 2 trial in bone and joint infections is being conducted in several countries comparing afabicin to standard antibiotics. About Debio 1453 Analogous to afabicin, the preclinical compound Debio 1453 is a potential first in class pathogen-specific drug targeting the essential bacterial fatty acid biosynthesis pathway. Debio 1453 is administered orally to treat Neisseria gonorrhoeae, the bacteria causing the sexually transmitted disease gonorrhea, a cause of serious and permanent health issues including infertility, ectopic pregnancy, cardiovascular and neurological problems. Debiopharm’s fight against antimicrobial resistance Debiopharm, an innovation-focused, Swiss biopharmaceutical company is one of the few privately owned companies developing novel class antibiotics to combat hard-to-treat infections. Through their unique partnership-based business model, the company is advancing pathogen-specific antibiotics from early stage through phase II clinical research with afabicin, specifically targeting staphylococci, being the most clinically advanced for the treatment of bone and joint infections. As a result of high selectivity, FabI inhibitors specifically target selected pathogens while preserving intestinal microbiota and meet all four WHO 2020 innovation criteria: new chemical class, new target, new mode of action and no cross-resistance to other antibiotic classes. For more information, please visit We are on Twitter. Follow us @DebiopharmNews at References [1] Morrison L, Zembower TR. Antimicrobial resistance. Gastrointest Endosc Clin N Am. 2020 Oct;30(4):619-635. [2] Antimicrobial resistance surveillance in Europe 2023–2021 data. [3] CDC Antibiotic resistance threats in the United States, 2019. [4] COVID-19 U.S. Impact on Antimicrobial Resistance. Disclosures * Speaker disclosures: Dr. McDonald has no relevant financial or non-financial relationships to disclose. The findings and conclusions of this presentation are those of the author and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the U.S. Department of Health and Human Services. Any use of trade names and commercial sources is for identification only and does not imply endorsement by the Centers for Disease Control and Prevention or the U.S. Department of Health and Human Services. View source version on businesswire.com: Contacts Debiopharm Contact Dawn Bonine Head of Communication dawn.bonine@debiopharm.com Tel: +41 (0)21 321 01 11 Source: Debiopharm View this news release online at:

International health authorities, such as the WHO and the CDC are warning of the emerging danger of bacterial infections resistant to current antibiotics The 2022 World Anti-Microbial Resistance (AMR) Congress in the greater Washington D.C. area is serving as a forum to openly address the threat of AMR Debiopharm will join the action-focused discussions around this silent pandemic in 3 panel discussions, presenting their microbiome-sparing FabI inhibitor class as a future tool to fight AMR LAUSANNE, Switzerland, Sept. 8, 2022 /PRNewswire/ -- Debiopharm, ( ) a privately-owned, Swiss-based, biopharmaceutical company committed to the development of novel class antibiotics, today revealed its involvement in three panel discussions at the World AMR Congress, taking place in Fort Washington, Maryland, from September 7th – 8th. This conference offers pharmaceutical companies, government, and policy stakeholders from all around the world the opportunity to meet, discuss and formulate initiatives to effectively tackle the emerging threat of antimicrobial resistance. Debiopharm will present developments on its FabI inhibitor antibiotic class including afabicin (Debio 1450), Debio 1453 and Debio 1454S, all of which have microbiome-sparing potential, a promising characteristic for AMR prevention. AMR is a leading cause of death and disability and represents a major threat to human health. Among the 1.27 million deaths1 that occur globally due to antibiotic-resistant infections each year, more than 35,0002 occur in the United States and over 33,0003 occur in Europe. The economic burden of AMR is also significant4 in direct health care and lost productivity costs are attributable to antibiotic-resistant bacteria like Staphylococcus spp. The WHO and the CDC have identified such pathogens posing a threat to public health and Debiopharm, one of the few private companies still engaged in the development of novel antibiotics, has directed its efforts toward targeting them. The World AMR summit offers a great opportunity to governments, funds, associations, and passionate companies like Debiopharm to join forces against one of the top global public threats facing humanity. "We're proud to unveil more on the role our novel class antibiotic, the FabI inhibitors, amongst key international stakeholders at the World AMR. We're hoping that our collaboration with specialized organizations and lawmakers will trigger the much needed changes in the way we think about the unmet need for antibiotics as well as provide hope to people and health practitioners dealing with these seemingly insurmountable infections," stated Mohammed Benghezal, Global Project Lead in Anti-infectives, Debiopharm. "Pathogen-specific antibiotic effect without harming the 'good' gut bacteria: it is the best of both worlds! As we research their efficacy and safety profile, this class of antibiotics could be like no other," expressed Ricardo Chaves, Executive Medical Director, Debiopharm. "Now is the time to encourage the development of new antibiotic classes by establishing new business models that will assure future patients access to effective treatments that will knock out highly resistant bacterial infections and at the same time prevent AMR development." About afabicin Afabicin (Debio 1450) is Debiopharm's first-in-class FabI inhibitor against Staphylococcus spp., whose sub-class Methicillin-resistant Staphylococcus aureus (MRSA) is high on the WHO global priority pathogen list and deemed a "serious threat" by the CDC. Afabicin can be administered orally or IV and selectively targets Staphylococcus' essential bacterial fatty acid biosynthesis. Promising results have been obtained in a comparative double-blind Phase 2 trial with afabicin in acute bacterial skin and skin structure infections. Currently, an international Phase 2 trial in bone and joint infections is being conducted comparing afabicin to standard antibiotics. About Debio 1453 and Debio 1454S Analogous to Afabicin, the preclinical compounds Debio 1453 and Debio 1454S are potential first-in-class pathogen-specific drugs targeting the essential bacterial fatty acid biosynthesis. Debio 1453 can be administered orally or intramuscularly to treat Neisseria gonorrhoeae infections while Debio 1454S is being developed for IV use in cases of hospital-acquired pneumonia and ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Debiopharm's fight against antimicrobial resistance Debiopharm, an innovation-focused, Swiss biopharmaceutical company is one of the few privately owned companies developing novel class antibiotics to combat hard-to-treat infections. Through their unique partnership-based business model, the company is advancing pathogen-specific antibiotics from early stage through phase II clinical research with afabicin, specifically targeting staphylococci, being the most clinically advanced for the treatment of bone and joint infections. As a result of high selectivity, FabI inhibitors specifically target selected pathogens while preserving intestinal microbiota and meet all four WHO 2020 innovation criteria: new chemical class, new target, new mode of action and no cross-resistance to other antibiotic classes. For more information, please visit We are on Twitter. Follow us @DebiopharmNews at Debiopharm Contact Dawn Haughton Communication Manager dawn.haughton@debiopharm.com Tel: +41 (0)21 321 01 11 References [1] Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629-655. [2] CDC Antibiotic resistance threats in the United States, 2019. [3] Cassini A, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56-66. [4] CDC Antibiotic resistance threats in the United States, 2013. SOURCE Debiopharm International SA